Paramolan

Quick links to important sections

Paramolan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paramolan

What is Paramolan? Overview

Property Description
Active Ingredient Paramol and Caffeine
Form Oral tablet, Capsule
Pharmacological Class Analgesic, Antipyretic (Enhanced Formulation)
Common Use Symptomatic relief of tension headache, fever, and minor pain
Origin Synthetic compound

Paramolan: What Kind of Medicine Is It?

Paramolan is a widely recognized, non-opioid medication classified as an analgesic (pain reliever) and an antipyretic (fever reducer), distinguished by its dual-component formulation.

Unlike single-ingredient pain relievers, Paramolan combines the core pain-relieving substance, Paramol, with a small amount of Caffeine. This formulation is typically intended for oral administration. This combined approach is intended to enhance the speed and effectiveness of the analgesic action. Paramolan is a first-line option often used for easing general discomfort where rapid action is desired.


What Is Paramolan Used for (Therapeutic Purpose)?

The general therapeutic purpose of Paramolan is to provide effective, temporary symptomatic relief from mild-to-moderate pain and elevated body temperature, particularly those associated with fatigue or tension.

It is frequently used for relieving symptoms such as tension headaches or the aching and fever that accompany common infections. Its inclusion of caffeine positions it specifically for pain relief where maintaining alertness is an objective. Substances with these analgesic and antipyretic properties are used for supporting the patient's well-being during acute, self-limiting conditions. This underscores Paramolan’s role in helping patients manage symptoms while their body recovers.

What side effects are possible with Paramolan?

Possible Side Effects and Safety Information

The safety profile of Paramolan, which contains Paracetamol and Caffeine, is defined by adverse reactions classified by official frequency and grouped by affected organ systems, according to regulatory standards.


Official Adverse Reaction Scope

Side effects are categorized primarily as Very Rare (may affect up to 1 in 10,000 people) or Not Known frequency (cannot be estimated from available data). Paracetamol-related serious effects are generally classified as Very Rare.

Classification System-Organ Class Examples Specific Reactions
Very Rare Hepatobiliary Disorders, Immune System Disorders, Blood and Lymphatic System Disorders, Skin and Subcutaneous Tissue Disorders Severe Hepatotoxicity, Anaphylaxis, Haematological reactions (e.g., Agranulocytosis), Severe skin reactions (SJS, TEN)
Not Known Psychiatric Disorders, Nervous System Disorders, Cardiac Disorders, Gastrointestinal Disorders Insomnia, Restlessness, Dizziness, Palpitations, Nausea

Serious Adverse Reactions and Safety Constraints

The most significant regulatory concern is the potential for Severe Hepatotoxicity (liver damage), which is primarily associated with Paracetamol overdose. Serious adverse reactions also include anaphylaxis and rare severe skin conditions, as explicitly documented in regulatory materials.

Official safety constraints are placed on specific populations. Use is not recommended during pregnancy or lactation. Additionally, patients with impaired liver or kidney function, those with chronic alcoholism, or those in glutathione-depleted states must exercise caution. A critical safety restriction is the strict prohibition on taking this product concurrently with any other medicine containing Paracetamol to prevent accidental dose stacking and potential toxicity. Time-related safety notes indicate that signs of liver injury may be delayed, becoming apparent 12 to 48 hours after ingestion.

Overdose and Emergency Response

The official regulatory documentation for Paramolan overdose describes the potential for serious, life-threatening outcomes, primarily focused on severe organ-specific toxicity.

Symptom Category Documented Manifestations
Early Toxicity Nausea, vomiting, pallor, and abdominal pain.
Severe Toxicity Jaundice and hepatic encephalopathy leading to acute liver failure.
Caffeine-Related Tachycardia (rapid heart rate), palpitations, and tremor.

When to Seek Immediate Medical Help

The official guidance mandates seeking medical attention immediately following a suspected overdose or the ingestion of excessive amounts. This action is required even if the individual is asymptomatic or feels well, due to the latency of severe toxicity.

The most serious outcomes documented include acute hepatic failure, which may lead to coma and death. Regulatory documents establish N-acetylcysteine (NAC) as the specific antidote required for Paracetamol (Paramol) toxicity. Management involves hospitalization, continuous clinical observation, monitoring of liver function tests, and measurement of the serum drug concentration to guide necessary supportive treatment. Increased risk of severe toxicity is specifically noted in individuals with chronic alcoholism or pre-existing liver impairment.

Therapeutic Uses of Paramolan

Paramolan is applied across domains where additional symptomatic support is needed for conditions associated with acute or disruptive episodes. The combination of Paracetamol and Caffeine is indicated for the management of common discomfort and elevated temperature.

Easing Mild to Moderate Pain and Common Headaches

Paramolan is generally used for the symptomatic relief of mild to moderate pain across various origins. It helps address symptoms related to physical discomfort, including tension-type headaches, general muscle aches, minor dental pain, and the cramping associated with primary dysmenorrhoea. This provides support that helps ease the overall symptom load during periods of heightened symptoms.

Managing Fever and Supporting Functional Alertness

The medication is relevant for easing symptoms related to physical discomfort, such as fever, and the generalized discomfort often associated with self-limiting conditions like colds and influenza. The formulation also helps address symptom clusters that create functional strain, and may assist with managing pain when maintaining alertness is important, supporting patients during episodes of heightened discomfort.


Quick Fact: Symptomatic Support Paramolan is commonly used across conditions presenting with acute episodes of pain and fever. It may assist with maintaining functional stability, and is intended to contribute to day-to-day comfort during symptomatic periods.

Regulatory References

  1. UK Medicines and Healthcare products Regulatory Agency (MHRA)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Paramolan — Official Regulatory Information

Paramolan (acetaminophen) is a widely available medicine, but its official regulatory labeling specifies clear rules for patient eligibility and contraindications to prevent serious risk, particularly liver injury. All eligibility is strictly tied to documented governmental health agency sources.


Eligibility Scope

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to acetaminophen or excipients.
Contraindicated Patients with severe hepatic impairment or severe active liver disease.
Caution/Restricted Patients with hepatic impairment, active liver disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment (creatinine clearance leq 30 mL/min).
Special Consideration Pregnancy/Lactation: Use only if clearly needed. Consult a healthcare professional.
Age-Related Eligibility Use is allowed across all ages (neonates onward) with weight-based dosing for pediatric patients. For specific intravenous formulations, efficacy in treating acute pain in patients younger than 2 years is not always established.

Official Eligibility Statements

The primary restriction is the prohibition of use in patients with severe active liver disease or a confirmed acetaminophen allergy. For individuals with moderate hepatic impairment or severe kidney impairment, the drug is not contraindicated but is restricted; official labeling mandates caution and may require dose adjustment or extended dosing intervals. Furthermore, the total daily dose from all sources containing acetaminophen must not exceed the maximum recommended limit for the patient's age/weight to avoid the risk of liver injury.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Co-administration with other paracetamol-containing products is strictly prohibited by regulatory bodies to prevent the risk of severe hepatic toxicity. The combination of the caffeine component with drugs like Clozapine, Theophylline, Ephedrine, and Beta-blockers is restricted in certain regulatory labels due to potential metabolic inhibition or increased cardiovascular effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Official Interaction Statement
Absorption Rate Change Metoclopramide, Domperidone May increase the speed of Paramol absorption from the gastrointestinal tract.
Anticoagulant Risk Warfarin and other Coumarins Prolonged regular daily use may enhance the anticoagulant effect, increasing the risk of bleeding.
Metabolism Risk Liver Enzyme Inducers (e.g., Phenytoin, Carbamazepine, Rifampicin, St. John's Wort) Increase the risk of Paracetamol hepatotoxicity due to the formation of a toxic metabolite.
Timing-Based Restriction Cholestyramine Reduces Paracetamol absorption; must be administered at least one hour after Paramolan.

Substance and Population-Specific Restrictions

Official regulatory information requires avoiding excessive intake of dietary caffeine and consumption of alcohol. Excessive caffeine intake may exacerbate adverse effects, and regular alcohol consumption is listed as a risk factor for Paracetamol-related liver damage. Caution is advised for interactions in patients with hepatic or renal impairment and those with existing risk factors for glutathione depletion when co-administered with certain antibiotics, such as Flucloxacillin.

Mechanism of Action

The mechanism of Paramolan involves a dual action targeting key signaling molecules and receptors, primarily within the central nervous system (CNS), to modulate nociceptive signaling and thermoregulatory processes.

Central Pathway Modulation for Nociception and Thermoregulation

Paramol's primary biological action is the inhibition of specific Cyclooxygenase (COX) enzymes located mainly in the CNS. This enzyme suppression reduces the synthesis of Prostaglandin E2 ( PGE2), a mediator that mediates the amplification of afferent nociceptive signals and affects the hypothalamic temperature set-point. The resulting physiological effect is the diminished central processing of nociceptive signals and the adjustment of the thermoregulatory set-point.

Neurotransmitter Antagonism and Mechanistic Synergy

The caffeine component acts as a competitive antagonist at central Adenosine Receptors ( A1 and A2 A). Blocking these inhibitory receptors promotes increased activity of stimulating neurotransmitters, leading to cerebral vasoconstriction and enhanced neural signaling. This neuro-modulation mechanistically enhances the speed and magnitude of the primary antinociceptive mechanism, contributing a synergistic effect to the overall action profile.

Dosage and Administration Information

How to Use Paramolan

Paramolan, a fixed-dose combination of Paracetamol (500 mg) and Caffeine (65 mg), is used according to standardized guidelines that define the route, dosage, frequency, and duration of use.


Official Administration Protocol

The designated route of administration for Paramolan is oral. It is available as film-coated tablets, which are swallowed whole with water, and soluble forms, which must be dissolved in at least half a glass of water prior to intake.

Dosing for Adults (ge 16 years): The standard single dose is two tablets, which corresponds to 1000 mg Paracetamol and 130 mg Caffeine. The dose may be repeated every four to six hours as needed, but the dosing interval must not be less than four hours. The maximum permitted intake is eight tablets in any 24-hour period.

Dosing for Adolescents (12 to 15 years): The labeled dose is one tablet up to four times daily, with a maximum of four tablets permitted within 24 hours. Use is not recommended for children under 12 years of age.


Use Constraints and Duration

The usage protocol establishes a short-term pattern, with continuous treatment limited to three consecutive days unless professional medical advice is sought. A key procedural condition requires individuals to avoid excessive consumption of other caffeine-containing products while using Paramolan to prevent exceeding the total daily intake of caffeine. Furthermore, it is required to avoid the concurrent use of Paramolan with any other product containing Paracetamol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paramolan


Evidence for Use in Acute Mild-to-Moderate Pain

Research was conducted to evaluate the Paramolan formulation, combining Paramol and Caffeine, for its application in acute, non-chronic pain. This research has primarily involved systematic reviews and meta-analyses that consolidate findings from multiple, short-term, controlled trials. These studies were used in research exploring how symptoms change over time and how outcomes related to physical discomfort evolve over defined time intervals. Populations included adults across various pain models, such as those experiencing post-operative pain and post-dental surgery discomfort.

Studies monitored several key measurements, including the proportion of individuals who reported a defined change in physical discomfort and the total patient-reported outcomes describing perceived discomfort over several hours. The overall evidence base contributes to understanding symptom patterns across trials regarding the short-term measurement of outcomes related to physical discomfort. Research limitation frames indicate that the majority of this evidence is chiefly limited to single-dose administration for acute outcomes describing episodic or acute changes.

Evidence for Use in Episodic Tension-Type Headache

Dedicated, double-blind randomized controlled trials (RCTs) were relevant in trials assessing short-term or episodic symptom patterns related to tension-type headaches. Research examined outcomes reflecting daily functioning or activity level and how participants responded to the combination during a period of heightened symptom activity. The primary focus was on the time required to achieve a measured reduction in symptom intensity and the patients' overall assessment of the experience. The evidence base for acute tension-type headache contributes to the broader evidence landscape in its capacity to address these short-term symptom changes.

What the Research Still Characterizes as Uncertain

Research highlights what is known—and what is still uncertain—about Paramolan. The evidence base is chiefly limited to the single-dose effects for acute outcomes related to physical discomfort, meaning long-term effects are not fully established regarding repeated or sustained use. Furthermore, comparative evidence is lacking for a full assessment against every single alternative over-the-counter analgesic agent in all indications. The data for certain groups remain insufficient; for instance, few data are available for older adults (≥65 years) or patients with specific, complex health conditions.

Key Studies & References Acetaminophen and Caffeine (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Paramolan (FAQ)


Q: How long does it typically take for Paramolan to start working?

Regulatory documents state that the caffeine component in Paramolan is included to help enhance the speed and magnitude of the primary pain-relief action. However, official patient-facing labels generally do not provide a specific universal time, such as '15 minutes', for when the effects begin.


Q: How long do the effects of Paramolan usually last?

Official administration guidelines are established based on the duration of effect of the active ingredients. This information defines that a dose may be repeated every four to six hours, which is the time window established by regulators for the drug's effect.


Q: Can Paramolan be taken with food?

The official product information states that the tablets are taken orally with water. The guidelines primarily focus on the correct route of administration. Dietary restrictions are generally not specified, but for any concerns about intake with food, the official label should be consulted.


Q: Is acceptable to crush or chew Paramolan tablets?

The official directions for film-coated tablets specify that they must be swallowed whole. Soluble forms have separate instructions for dissolving them in water. The label does not include authorization for crushing or chewing film-coated tablets.


Q: Are there any known interactions between Paramolan and herbal supplements?

Regulatory documents advise caution when combining Paramolan with certain herbal products. Specific substances like St. John's Wort are mentioned because they can affect liver enzymes, which may increase the potential for the Paracetamol component to cause liver damage.


Q: What is the official information regarding Paramolan use in older adults?

Official information from regulatory research frames often notes a limitation in available data for individuals aged 65 and over. This means the effects and safety profile of the drug are not as fully characterized in older adults as they are in younger populations.


Q: Does Paramolan carry a warning about potential skin reactions?

Yes, regulatory safety data includes a warning about the potential for rare, severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These are classified as very rare adverse reactions in the official safety profile.


Q: If Paramolan is described as having potential interactions, what category of drugs is usually involved?

The drugs involved in regulatory warnings primarily include agents that affect the rate of absorption (like Metoclopramide), blood clotting (anticoagulants like Warfarin), or liver enzyme activity (like enzyme inducers). The official label provides specific details on these categories.


Q: Can Paramolan be taken if a person has high blood pressure?

High blood pressure itself is not an explicit contraindication for the analgesic component in regulatory materials. However, the caffeine component may be restricted or advised against in individuals with certain heart conditions or those taking blood pressure medications (like Beta-blockers), necessitating review of the official label.


Q: Is Paramolan an over-the-counter medicine or does it require a prescription?

In many regions globally, Paramolan is generally available as an over-the-counter (OTC) medicine. However, official regulatory classifications can vary by country, and certain specific formulations or higher strengths containing the active ingredients may be classed as prescription-only.


Q: Does Paramolan contain any non-medicinal ingredients people should know about?

Yes, official labeling, such as the Summary of Product Characteristics, lists all inactive ingredients, also called excipients. This information is provided because known hypersensitivity to any listed excipients is a contraindication listed in official product information.


Q: What is the difference between Paramolan and (another common analgesic)?

Paramolan is officially defined as a dual-component combination of Paramol (Paracetamol) and Caffeine, classified as a non-opioid analgesic and antipyretic. Other common analgesics may differ by being single-ingredient products or belonging to different pharmacological classes, such as NSAIDs.


Q: Why is Paramolan sometimes combined with other substances in certain products?

Official regulatory documents approve Paramolan as a combination product because the added caffeine is intended to enhance the speed and effectiveness of the pain relief. When combined with other agents in different products (like cold and flu medicines), it is to address the multiple symptoms of that specific condition.


Q: Can Paramolan cause drowsiness or affect driving?

The official adverse reaction profile for Paramolan lists side effects such as dizziness and restlessness, though the frequency is 'Not Known.' Because the drug contains caffeine, there is generally no warning of drowsiness, but some product labels include a warning regarding caution when driving or operating machinery.


Q: Is it normal to feel a mild stomach upset after taking Paramolan?

Official safety data for Paramolan lists Nausea under Gastrointestinal Disorders. This side effect is typically classified with a frequency of 'Not Known' or similarly non-common grading, meaning this reaction is not characterized with a common or frequent occurrence rating in the official safety documents.


Q: Is there a risk of developing a dependency on Paramolan?

Paramolan (Paracetamol/Caffeine) is classified as a non-opioid medicine, and regulatory documents do not typically include a warning for addiction or physical dependence for this specific combination. However, the label does include constraints on the maximum duration of continuous use for pain relief.


Q: Can Paramolan affect the results of any common lab tests?

Official precautions note that the active ingredient, Paracetamol, has been documented to interfere with certain common laboratory tests, particularly those that measure blood glucose levels. This interference could potentially lead to inaccurate readings from some monitoring devices.


Q: Why might a doctor suggest Paramolan instead of a different pain reliever?

Regulatory information indicates that the drug is distinguished by its dual-action combination. This formulation offers a neuro-modulatory effect that is intended to enhance the speed and magnitude of the analgesic action, which is a key feature that distinguishes its therapeutic profile.


Q: Does Paramolan come in different strengths or concentrations?

Yes, regulatory documents list the availability of specific fixed-dose concentrations, most commonly Paracetamol 500 mg combined with Caffeine 65 mg. Other authorized strengths may be available depending on the specific product formulation and the country of approval.


Q: Is the Paramolan brand name the same as the generic version?

A generic version is required by regulators to contain the exact same active ingredients (Paramol and Caffeine) at the same strength, dosage form, and route as the brand-name product. The key distinctions permitted are typically limited to differences in price, appearance, or non-medicinal ingredients.


Q: Are there specific official warnings about taking Paramolan with certain foods or drinks?

Official warnings specifically advise individuals to avoid or limit the excessive consumption of dietary caffeine and to strictly prohibit the consumption of alcohol. These constraints are in place to prevent exceeding the total daily safe limit for caffeine and to reduce the risk of liver damage.


Q: Are there any known interactions between Paramolan and caffeine?

Paramolan itself contains caffeine, and regulatory constraints do not list an interaction with caffeine as a separate substance. However, the official guidance strictly requires individuals to avoid excessive consumption of dietary caffeine to ensure the total daily intake remains within established safe limits.


Q: Can Paramolan affect a person's sleep patterns?

Official documents list side effects such as Insomnia and Restlessness, classified under Nervous or Psychiatric disorders. These effects are typically linked to the known stimulating action of the caffeine component in the formulation.


Q: Can Paramolan affect blood sugar levels?

While the drug is not generally listed as affecting blood sugar levels directly, the Paracetamol component is known to interfere with the readings of certain Continuous Glucose Monitoring (CGM) devices. This interference could potentially lead to inaccurate blood sugar measurements.


Q: How does Paramolan work to help reduce fever?

According to official mechanism of action descriptions, the drug helps reduce fever by inhibiting specific enzymes in the central nervous system. This action helps to adjust the part of the brain that controls body temperature (the hypothalamic thermoregulatory set-point) to a lower level.


Q: Is Paramolan described as helpful for tension headaches?

Yes, the official therapeutic uses listed in regulatory documents explicitly include the symptomatic relief of tension-type headache. This indication is supported by clinical trials and evidence assessed during the drug's approval process.


Q: What should a person do if they suspect an interaction with Paramolan?

Official patient information states that if an individual experiences symptoms of an adverse reaction or suspects a drug interaction, the regulatory guidance is to discontinue use of the medication and seek medical attention for evaluation.


Q: What are the general expectations about the Paramolan component's impact on inflammation?

The drug is officially classified as an analgesic (pain reliever) and antipyretic (fever reducer). Its primary mechanism of action is central, meaning it does not generally result in the strong peripheral anti-inflammatory action that is associated with other classes of pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs).

How should Paramolan be stored and disposed of?

How to Store and Dispose of Paramolan

The storage and disposal requirements for Paramolan are based strictly on official regulatory labeling to ensure product quality and safety.

Required Storage Conditions

Paramolan must be stored at a temperature not exceeding 25°C or 30°C, as specified by the regulatory document for the specific formulation. The medicine must be kept in a cool, dry place and protected from light and moisture. To maintain its stability, the product should be kept from freezing and stored in its original package.

Child Safety and Disposal

It is mandatory that Paramolan be kept out of the sight and reach of children and infants at all times. The medicine must not be used after the expiry date printed on the packaging. When disposing of unused or expired product, it must not be thrown away via wastewater or household waste; instead, it should be disposed of in accordance with local requirements, often by returning it to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paramolan found in:

A-Z Index: